ACE-031
Research profile · How we handle evidence
ACE-031 is an experimental myostatin-pathway inhibitor being studied for muscle wasting and related conditions. Myostatin is a signaling protein that helps regulate muscle growth.
Evidence Score
Moderate confidence
Category
Therapeutic area
Standard Dose
Weekly
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Monitor closely
Overview
ACE-031 is designed to interfere with myostatin signaling, which can be relevant when researchers want to encourage muscle-related changes. In early human studies, investigators looked at pharmacology, muscle/lean-mass signals, and tolerability. That’s different from a guarantee of visible gains for every user—responses and risks can vary, and long-term safety isn’t established.
Mechanism of Action
ACE-031 is designed to interfere with myostatin signaling, which can be relevant when researchers want to encourage muscle-related changes. In early human studies, investigators looked at pharmacology, muscle/lean-mass signals, and tolerability. That’s different from a guarantee of visible gains for every user—responses and risks can vary, and long-term safety isn’t established.
Benefits
- Significant muscle growth
- Myostatin inhibition
- Increased muscle mass
- Strength gains
Side Effects
- Injection-site reactions (redness, discomfort) reported in studies
- Headache or fatigue reported in some contexts
- Long-term safety is not well characterized
Contraindications
- Pregnancy or breastfeeding
- Minors
- People with active malignancy or significant medical comorbidities—use only with clinician guidance
- Known hypersensitivity to the peptide components
Structure & Sequence
Verified structure
ACE-031
Illustration uses the catalog amino acid sequence because no exact external registry match was confirmed.
- Amino Acid Sequence
- Recombinant fusion protein: extracellular domain of human activin receptor type IIB (ActRIIB) fused to a human IgG1 Fc domain (~370 residues total) — a soluble decoy receptor, not a short synthesized peptide, so no compact literal sequence is listed here
- CAS Number
- N/A
Stack & Route Context
Stacks with
No entries listed.
Administration
Subcutaneous
Research Status
Investigational (clinical research) myostatin-pathway inhibitor
Approval Status
Phase2
Sports Legal
Restricted
References
- 1View source
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (ClinicalTrials.gov)
2009
- 2View source
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers (PubMed)
2013
- 3View source
Myostatin inhibitor ACE-031 treatment in boys with Duchenne muscular dystrophy (PubMed)
2016
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.